The first draft guidelines for copy biologicals were introduced in China back in 2014. The Technical Guideline was then updated and finalized in 2015. In this paper, how the Drug Registration Regulation (2007) pathway classifies therapeutic biologicals and the principles and challenges of the copy biologicals guideline are described.
Submitted: 3 May 2018; Revised: 8 May 2018; Accepted: 15 May 2018; Published online first: 25 May 2018
China has a huge market for copy biologicals, with 40% of China’s US$1.5 billion recombinant biologicals sales coming from copy biologicals, which have enjoyed compound annual growth rate (CAGR) of approximately 25−30% over the past decade. With predicted market growth of 25% per year, the Chinese copy biologicals market was expected to grow to US$2 billion. This makes it an attractive market to move into for more and more multinational biosimilars makers.
China first introduced draft guidelines for copy biologicals back in 2014 . The Technical Guideline was then updated and finalized in 2015 . The legal structure of the current Chinese copy biologicals guideline is based on the Drug Administration Law (Revised 2015) issued by the Chinese Government and on the Drug Registration Regulation (Revised 2007) issued by the China Food and Drug Administration (CFDA).
CFDA (simplified Chinese: ) has been the Chinese authority that oversees all drug manufacturing, trade and registration in the country since 2003 .
The Drug Registration Regulation (Revised 2007) pathway classifies therapeutic biologicals into 15 categories :
1. Products that have not been marketed in China and other countries
2. Monoclonal antibodies
3. Gene therapy, somatic cell therapy and related products
4. Allergen products
5. Multicomponent bioactive products extracted from human/animal tissue/body fluid, or produced by fermentation
6. New combination products made from marketed biological
7. Products which have been marketed in other countries but not China
8. Microbiological products containing components made from strains that have not been approved for use in China
9. Products that do not have the exact same structure as marketed products and have not been marketed in China or overseas (including locus mutation or absence of amino acid, changes in post-translational mutation or absence of amino acid, changes in post-translational modification caused by using different expression systems, and chemical modification of the product)
10. Biologicals produced by different methods compared with the marketed products, such as different expression systems, or host cells
11. The first product produced by recombinant DNA method (for example, replacement of synthesis, tissue extraction or fermentation technologies by recombinant DNA technology)
12. Products changed from non-injection route to injection route or from topical use to systemic use, which have not been marketed in China or other countries
13. Marketed products with a new formulation but same route of administration
14. Marketed products with a new route of administration (excluding Category 12)
15. Products with national standards
The Chinese copy biologicals guideline is based on four principles:
These core principles should be used across the entire R & D and evaluation process, see Figure 1.
Figure 1 pending to upload
The updated and finalized Technical Guideline for copy biologicals  provides a relatively clear regulatory pathway for development of copy biologicals in China. It clarifies some confusion and provides the principles of R & D and evaluation for copy biologicals. It also helps to regulate activities and speed up the entire process. The guideline is also intended to raise the bar for entry into the copy biologicals field, avoiding low quality competition.
The Technical Guideline follows similar standards and principles as guidelines from other major markets. This, it is hoped, will increase the quality of products produced in the country and make them more competitive, as well as increase the possibility of marketing Chinese copy biologicals in other countries.
The main challenges with respect to the guideline include:
• Significantly increased R & D costs
• Availability of reference product for clinical trials
– ‘reference product for clinical trials should be approved in China’
• Basically impossible to waive phase III comparative trials
• Extrapolation of indications limited to indications approved in China
• Too general and impractical
• Some requirements are too stringent
It should be noted that ‘copy biologicals’ approved in China might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the European Union. The European Medicines Agency regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.
Competing interests: None.
Provenance and peer review: Commissioned; externally peer reviewed.
Michelle Derbyshire, PhD, GaBI Online Editor
References pending to upload
Disclosure of Conflict of Interest Statement is available upon request.
Copyright © 2018 Pro Pharma Communications International
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.